177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer

Gibbens-Bandala, Brenda; Morales-Ávila, Enrique; Ferro-Flores, Guillermina; Santos-Cuevas, Clara; Meléndez‐Alafort, Laura; Trujillo-Nolasco, Maydelid; Ocampo‐García, Blanca

doi:10.1016/j.msec.2019.110043

Cited by 48 publications

(39 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo studies showed a significant accumulation in the tumor‐bearing mouse model after 72 h. Therefore, these micelles are proposed as suitable strategies for bimodal breast cancer therapy due to the synergistic effect of 177 Lu and PTX, in addition it could be useful to record and monitor the disease progression by molecular imaging through the gamma emission. [ 61 ]…”

Section: Polymeric Nanoparticles For Imaging and Therapymentioning

confidence: 99%

Drug Delivery Systems‐Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy

Aranda-Lara

Ocampo‐García

Isaac‐Olivé

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

Polymeric nanoparticles encompass micelles and dendrimers. They are used for improving or controlling the action of the loaded therapy or imaging agent, including radionuclides. Some radionuclides possess properties appropriate for simultaneous imaging and therapy of a disease and are therefore called theranostic. The diversity in core materials and surface modification, as well as radiolabeling strategies, offers multiples possibilities for preparing polymeric nanoparticles using radionuclides. The present review describes different strategies in the preparation of such nanoparticles and their applications in nuclear nanomedicine.

show abstract

Section: Polymeric Nanoparticles For Imaging and Therapymentioning

confidence: 99%

Drug Delivery Systems‐Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy

Aranda-Lara

Ocampo‐García

Isaac‐Olivé

et al. 2021

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…These results suggested that 111 In-hEGF-PLGA-Ru1 NPs can be an interesting option for EGFR-overexpressed esophageal cancer treatment (Gill et al., 2018 ). Gibbens-Bandala and colleagues ( 2019 ) investigated the breast cancer therapy using 177 Lu-BN-PLGA NPs and 177 Lu-BN-PLGA NPs containing paclitaxel (PTX). According to the in vivo studies, they observed that 177 Lu-BN-PLGA-PTX NPs showed the lowest tumor proliferation, followed by PLGA-PTX NPs and 177 Lu-BN-PLGA NPs.…”

Section: Radioactive Polymeric Nanoparticles For Imaging and Therapymentioning

confidence: 99%

“…According to the in vivo studies, they observed that 177 Lu-BN-PLGA-PTX NPs showed the lowest tumor proliferation, followed by PLGA-PTX NPs and 177 Lu-BN-PLGA NPs. Also, 177 Lu-BN-PLGA-PTX NPs presented the lowest metabolic tumoral activity, indicating that the combination of drug, polymer and radioactive agent increase the therapeutical response (Gibbens-Bandala et al., 2019 ).…”

Section: Radioactive Polymeric Nanoparticles For Imaging and Therapymentioning

confidence: 99%

“…Gibbens-Bandala and colleagues evaluated a paclitaxel PLGA NP conjugated with bombesin (gastrin-releasing peptide that binds to gastrin receptors overexpressed in breast cancer) labeled with 177 Lu. They observed a controlled release of paclitaxel as well as a higher uptake of tumor cells suggesting an interesting system with therapeutic and diagnostic effects (Gibbens-Bandala et al., 2019 ). Another system described for breast cancer treatment and detection was based on magnetic NPs coated with chitosan, conjugated with a radioisotope chelator and bombesin labeled with 68 Ga.…”

Section: Radioactive Polymeric Nanoparticles For Biomedical Applicatimentioning

confidence: 99%

See 1 more Smart Citation

Radioactive polymeric nanoparticles for biomedical application

Wu¹,

Helal-Neto

Matos

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Nowadays, emerging radiolabeled nanosystems are revolutionizing medicine in terms of diagnostics, treatment, and theranostics. These radionuclides include polymeric nanoparticles (NPs), liposomal carriers, dendrimers, magnetic iron oxide NPs, silica NPs, carbon nanotubes, and inorganic metal-based nanoformulations. Between these nano-platforms, polymeric NPs have gained attention in the biomedical field due to their excellent properties, such as their surface to mass ratio, quantum properties, biodegradability, low toxicity, and ability to absorb and carry other molecules. In addition, NPs are capable of carrying high payloads of radionuclides which can be used for diagnostic, treatment, and theranostics depending on the radioactive material linked. The radiolabeling process of nanoparticles can be performed by direct or indirect labeling process. In both cases, the most appropriate must be selected in order to keep the targeting properties as preserved as possible. In addition, radionuclide therapy has the advantage of delivering a highly concentrated absorbed dose to the targeted tissue while sparing the surrounding healthy tissues. Said another way, radioactive polymeric NPs represent a promising prospect in the treatment and diagnostics of cardiovascular diseases such as cardiac ischemia, infectious diseases such as tuberculosis, and other type of cancer cells or tumors.

show abstract

“…Therefore, it is an urgent task to design and construct new delivery system of antitumor drugs for tumor treatment with high efficiency and low toxicity. Sustained and/or targeted release formulations can make the tumor tissues exposed to high-concentration antitumor drugs for a long time, thus avoiding the inconvenience caused by continuous administration, and minimizing the toxic and side effects of antitumor drugs because of relatively low drug uptake by systemic normal cells thanks to tumor local administration (Jung et al, 2018;Chen et al, 2019;Fan et al, 2019;Gibbens-Bandala et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Research progress in the application of in situ hydrogel system in tumor treatment

Wei

Yin

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

The in situ hydrogel drug delivery system is a hot research topic in recent years. Combining both properties of hydrogel and solution, in situ hydrogels can provide many advantages for drug delivery application, including easy application, high local drug concentration, prolonged drug retention time, reduced drug dose in vivo, good biocompatibility and improved patient compliance, thus has potential in tumor treatment. In this paper, the related literature reports in recent years were reviewed to summarize and discuss the research progress and development prospects in the application of in situ hydrogels in tumor treatment. ARTICLE HISTORY

show abstract

177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer

Cited by 48 publications

References 33 publications

Drug Delivery Systems‐Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy

Drug Delivery Systems‐Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy

Radioactive polymeric nanoparticles for biomedical application

Research progress in the application of in situ hydrogel system in tumor treatment

Contact Info

Product

Resources

About